NYSE - Delayed Quote • USD
Johnson & Johnson (JNJ)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 21 | 22 |
| Avg. Estimate | 2.71 | 2.7 | 10.65 | 10.99 |
| Low Estimate | 2.63 | 2.57 | 10.57 | 10.46 |
| High Estimate | 2.84 | 2.8 | 10.85 | 11.53 |
| Year Ago EPS | 2.56 | 2.66 | 9.92 | 10.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 22 | 22 |
| Avg. Estimate | 22.31B | 22.2B | 88.39B | 90.81B |
| Low Estimate | 21.9B | 22.07B | 88.03B | 89.95B |
| High Estimate | 22.61B | 22.33B | 89.29B | 91.83B |
| Year Ago Sales | 25.53B | 21.03B | 85.16B | 88.39B |
| Sales Growth (year/est) | -12.60% | 5.50% | 3.80% | 2.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 2.62 | 2.52 | 2.28 | 2.64 |
| EPS Actual | 2.56 | 2.66 | 2.29 | 2.71 |
| Difference | -0.06 | 0.14 | 0.01 | 0.07 |
| Surprise % | -2.30% | 5.60% | 0.40% | 2.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 2.71 | 2.7 | 10.65 | 10.99 |
| 7 Days Ago | 2.72 | 2.73 | 10.65 | 11.02 |
| 30 Days Ago | 2.73 | 2.73 | 10.66 | 11.04 |
| 60 Days Ago | 2.73 | 2.73 | 10.66 | 11.04 |
| 90 Days Ago | 2.72 | 2.76 | 10.67 | 11.14 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | 2 | 5 | 4 |
| Up Last 30 Days | 4 | 2 | 5 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 9 | 11 | 5 | 9 |
Growth Estimates
| CURRENCY IN USD | JNJ | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 5.90% | -- | -- | 1.60% |
| Next Qtr. | 1.50% | -- | -- | 10.50% |
| Current Year | 7.40% | -- | -- | 5.20% |
| Next Year | 3.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 5.23% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 5.44% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Upgrade | HSBC: Hold to Buy | 4/18/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 4/17/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/17/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/17/2024 |
| Maintains | B of A Securities: Neutral to Neutral | 4/17/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
Related Tickers
PFE Pfizer Inc.
26.00
+2.40%
ABBV AbbVie Inc.
166.41
+1.06%
LLY Eli Lilly and Company
726.31
-2.63%
BMY Bristol-Myers Squibb Company
48.93
+1.30%
MRK Merck & Co., Inc.
125.78
+0.44%
AMGN Amgen Inc.
268.93
+2.35%
GILD Gilead Sciences, Inc.
66.76
+0.91%
BIIB Biogen Inc.
194.38
+2.03%
AZN AstraZeneca PLC
68.55
+0.28%
GSK GSK plc
39.75
+1.22%